

For 08 / 484312

Attachment
to Paper No.
19

X

EXHIBIT A

49. A polypeptide according to claim 83, wherein said polypeptide includes at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and at the carboxyl-terminus.
50. A polypeptide according to claim 49, wherein said polypeptide includes at least one additional amino acid at the amino-terminus and at the carboxyl-terminus.
51. A polypeptide according to claim 49, wherein said polypeptide includes at least one additional amino acid at the amino-terminus.
52. A polypeptide according to claim 51, wherein said polypeptide includes a methionine at the amino-terminus.
53. A polypeptide according to claim 49, wherein said polypeptide includes at least one additional amino acid at the carboxyl-terminus.
67. A pharmaceutical composition comprising a polypeptide of claim 69 and a pharmaceutically acceptable carrier.
68. A pharmaceutical composition comprising a polypeptide of claim 83 and a pharmaceutically acceptable carrier.
69. (Amended) A recombinant polypeptide which is nonglycosylated or is glycosylated by a CHO cell which has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:

A) DNA comprising the sequence:

R ²	GAT	AGT	GTG	TGT	CCC	CAA	GGA	AAA	TAT	ATC	CAC
CCT	CAA	AAT	AAT	TCG	ATT	TGC	TGT	ACC	AAG	TGC	CAC

AAA	GGA	ACC	TAC	TTG	TAC	AAT	GAC	TGT	CCA	GGC	CCG
GGG	CAG	GAT	ACG	GAC	TGC	AGG	GAG	TGT	GAG	AGC	GGC
TCC	TTC	ACC	GCT	TCA	GAA	AAC	CAC	CTC	AGA	CAC	TGC
CTC	AGC	TGC	TCC	AAA	TGC	CGA	AAG	GAA	ATG	GGT	CAG
GTG	GAG	ATC	TCT	TCT	TGC	ACA	GTG	GAC	CGG	GAC	ACC
GTG	TGT	GGC	TGC	AGG	AAG	AAC	CAG	TAC	CGG	CAT	TAT
TGG	AGT	GAA	AAC	CTT	TTC	CAG	TGC	TTC	AAT	TGC	AGC
CTC	TGC	CTC	AAT	GGG	ACC	GTG	CAC	CTC	TCC	TGC	CAG
GAG	AAA	CAG	AAC	ACC	GTG	TGC	ACC	TGC	CAT	GCA	GGT
TTC	TTT	CTA	AGA	GAA	AAC	GAG	TGT	GTC	TCC	TGT	AGT
AAC	TGT	AAG	AAA	AGC	CTG	GAG	TGC	ACG	AAG	TTG	TGC
CTA	CCC	CAG	ATT	GAG	AAT						

, or a C- and/or N- terminally shortened sequence thereof, wherein R² is absent or is a DNA comprising a sequence coding for a polypeptide which can be cleaved *in vivo*; and

B) DNA comprising the sequence:

R ²	GAT	AGT	GTG	TGT	CCC	CAA	GGA	AAA	TAT	ATC	CAC
	CCT	CAA	AAT	AAT	TCG	ATT	TGC	TGT	ACC	AAG	TGC
	CAC	AAA	GGA	ACC	TAC	TTG	TAC	AAT	GAC	TGT	CCA
	GGC	CCG	GGG	CAG	GAT	ACG	GAC	TGC	AGG	GAG	TGT
	GAG	AGC	GGC	TCC	TTC	ACC	GCT	TCA	GAA	AAC	CAC
	CTC	AGA	CAC	TGC	CTC	AGC	TGC	TCC	AAA	TGC	CGA
	AAG	GAA	ATG	GGT	CAG	GTG	GAG	ATC	TCT	TCT	TGC
	ACA	GTG	GAC	CGG	GAC	ACC	GTG	TGT	GGC	TGC	AGG
	AAG	ATC	CAG	TAC	CGG	CAT	TAT	TGG	AGT	GAA	AAC
	CTT	TTC	CAG	TGC	TTC	AAT	TGC	AGC	CTC	TGC	CTC
	AAT	GGG	ACC	GTG	CAC	CTC	TCC	TGC	CAG	GAG	AAA
	CAG	AAC	ACC	GTG	TGC	ACC	TGC	CAT	GCA	GGT	TTC
	TTT	CTA	AGA	GAA	AAC	GAG	TGT	GTC	TCC	TGT	AGT
	AAC	TGT	AAG	AAA	AGC	CTG	GAG	TGC	ACG	AAG	TTG
	TGC	CTA	CCC	CAG	ATT	GAG	AAT	GTT	AAG	GGC	ACT
	GAG	GAC	TCA	GGC	ACC	ACA					

, or a C- and/or N- terminally shortened sequence thereof, wherein R² is absent or represents DNA coding for a polypeptide which can be cleaved *in vivo*;

C) a DNA sequence of A or B encoding at least one conservative amino acid substitution;

D) a DNA sequence of A or B encoding at least one amino acid substitution at a glycosylation site;

E) a DNA sequence of A or B encoding at least one amino acid substitution at a proteolytic cleavage site; and

F) a DNA sequence of A or B encoding at least one amino acid substitution at a cysteine residue.

70. (Amended) A polypeptide according to claim 69, wherein R^2 is a DNA comprising a sequence which codes for a polypeptide which can be cleaved *in vivo*.

71. (Amended) A polypeptide according to claim 69, wherein R^2 is a DNA comprising the sequence: CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA, or a C- and/or N- terminally shortened sequence thereof.

72. (Amended) A polypeptide according to claim 69, wherein R^2 is a DNA encoding an amino acid sequence comprising: leu val pro his leu gly asp arg glu lys arg, or a C- and/or N- terminally shortened sequence thereof.

73. (Amended) A polypeptide according to claim 70, wherein R^2 is a DNA comprising the sequence: R^3 CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA, or a C- and/or N- terminally shortened sequence thereof, wherein R^3 is a DNA coding for a signal peptide.

74. (Amended) A polypeptide according to claim 70, wherein R^2 is a DNA encoding an amino acid sequence comprising: R^3 leu val pro his leu gly asp arg glu lys arg, or a C- and/or N- terminally shortened sequence thereof, wherein R^3 is a DNA coding for a signal peptide.

75. (Amended) A polypeptide according to claim 73, wherein R^3 is a DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA
 CTG GTG CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC
 TCA GGG GTT ATT GGA

; or a C- and/or N- terminally shortened sequence thereof.

76. Polypeptide according to claim 73, wherein R³ is a DNA encoding an amino acid sequence comprising:

met gly leu ser thr val pro asp leu leu leu pro leu val
 leu leu glu leu leu val gly ile tyr pro ser gly val ile
 gly

; or a C- and/or N- terminally shortened sequence thereof.

78. (Amended) A recombinant polypeptide which is nonglycosylated or is glycosylated by a CHO cell and has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:

A) DNA comprising the sequence:

CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT
 AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA
 AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA
 ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GGG CAG
 GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC TTC
 ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC AGC
 TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG
 ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT
 GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT
 GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC
 CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA
 CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC TTT
 CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC TGT
 AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA CCC
 CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof;

B) DNA comprising the sequence:

CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT
 AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA

AAT	AAT	TCG	ATT	TGC	TGT	ACC	AAG	TGC	CAC	AAA	GGA
ACC	TAC	TTG	TAC	AAT	GAC	TGT	CCA	GGC	CCG	GGG	CAG
GAT	ACG	GAC	TGC	AGG	GAG	TGT	GAG	AGC	GGC	TCC	TTC
ACC	GCT	TCA	GAA	AAC	CAC	CTC	AGA	CAC	TGC	CTC	AGC
TGC	TCC	AAA	TGC	CGA	AAG	GAA	ATG	GGT	CAG	GTG	GAG
ATC	TCT	TCT	TGC	ACA	GTG	GAC	CGG	GAC	ACC	GTG	TGT
GGC	TGC	AGG	AAG	AAC	CAG	TAC	CGG	CAT	TAT	TGG	AGT
GAA	AAC	CTT	TTC	CAG	TGC	TTC	AAT	TGC	AGC	CTC	TGC
CTC	AAT	GGG	ACC	GTG	CAC	CTC	TCC	TGC	CAG	GAG	AAA
CAG	AAC	ACC	GTG	TGC	ACC	TGC	CAT	GCA	GGT	TTC	TTT
CTA	AGA	GAA	AAC	GAG	TGT	GTC	TCC	TGT	AGT	AAC	TGT
AAG	AAA	AGC	CTG	GAG	TGC	ACG	AAG	TTG	TGC	CTA	CCC
CAG	ATT	GAG	AAT	GTT	AAG	GGC	ACT	GAG	GAC	TCA	GGC
ACC	ACA										

, or a C- and/or N- terminally shortened sequence thereof;

C) DNA comprising the sequence:

GAT	AGT	GTG	TGT	CCC	CAA	GGA	AAA	TAT	ATC	CAC	CCT
CAA	AAT	AAT	TCG	ATT	TGC	TGT	ACC	AAG	TGC	CAC	AAA
GGA	ACC	TAC	TTG	TAC	AAT	GAC	TGT	CCA	GGC	CCG	GGG
CAG	GAT	ACG	GAC	TGC	AGG	GAG	TGT	GAG	AGC	GGC	TCC
TTC	ACC	GCT	TCA	GAA	AAC	CAC	CTC	AGA	CAC	TGC	CTC
AGC	TGC	TCC	AAA	TGC	CGA	AAG	GAA	ATG	GGT	CAG	GTG
GAG	ATC	TCT	TCT	TGC	ACA	GTG	GAC	CGG	GAC	ACC	GTG
TGT	GGC	TGC	AGG	AAG	AAC	CAG	TAC	CGG	CAT	TAT	TGG
AGT	GAA	AAC	CTT	TTC	CAG	TGC	TTC	AAT	TGC	AGC	CTC
TGC	CTC	AAT	GGG	ACC	GTG	CAC	CTC	TCC	TGC	CAG	GAG
AAA	CAG	AAC	ACC	GTG	TGC	ACC	TGC	CAT	GCA	GGT	TTC
TTT	CTA	AGA	GAA	AAC	GAG	TGT	GTC	TCC	TGT	AGT	AAC
TGT	AAG	AAA	AGC	CTG	GAG	TGC	ACG	AAG	TTG	TGC	CTA
CCC	CAG	ATT	GAG	AAT							

, or a C- and/or N- terminally shortened sequence thereof; and

D) DNA comprising the sequence:

GAT	AGT	GTG	TGT	CCC	CAA	GGA	AAA	TAT	ATC	CAC	CCT
CAA	AAT	AAT	TCG	ATT	TGC	TGT	ACC	AAG	TGC	CAC	AAA
GGA	ACC	TAC	TTG	TAC	AAT	GAC	TGT	CCA	GGC	CCG	GGG
CAG	GAT	ACG	GAC	TGC	AGG	GAG	TGT	GAG	AGC	GGC	TCC
TTC	ACC	GCT	TCA	GAA	AAC	CAC	CTC	AGA	CAC	TGC	CTC
AGC	TGC	TCC	AAA	TGC	CGA	AAG	GAA	ATG	GGT	CAG	GTG
GAG	ATC	TCT	TCT	TGC	ACA	GTG	GAC	CGG	GAC	ACC	GTG
TGT	GGC	TGC	AGG	AAG	AAC	CAG	TAC	CGG	CAT	TAT	TGG
AGT	GAA	AAC	CTT	TTC	CAG	TGC	TTC	AAT	TGC	AGC	CTC

TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG
AAA CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC
TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC
TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA
GGC ACC ACA

, or a C- and/or N- terminally shortened sequence thereof;

E) a DNA sequence of A, B, C or D encoding at least one conservative amino acid substitution;

F) a DNA sequence of A, B, C or D encoding at least one amino acid substitution at a glycosylation site;

G) a DNA sequence of A, B, C or D encoding at least one amino acid substitution at a proteolytic cleavage site; and

H) a DNA sequence of A, B, C or D encoding at least one amino acid substitution at a cysteine residue.

80. (Amended) A recombinant polypeptide which is nonglycosylated or is glycosylated by a CHO cell and has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:

A) DNA comprising the sequence:

ATG CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA
GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT
CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA
GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GGG
CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC
TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC
AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG
TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG
AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC
TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG
AAA CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC
TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC
TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof;

B) DNA comprising the sequence:

ATG	CTG	GTC	CCT	CAC	CTA	GGG	GAC	AGG	GAG	AAG	AGA
GAT	AGT	GTG	TGT	CCC	CAA	GGA	AAA	TAT	ATC	CAC	CCT
CAA	AAT	AAT	TCG	ATT	TGC	TGT	ACC	AAG	TGC	CAC	AAA
GGA	ACC	TAC	TTG	TAC	AAT	GAC	TGT	CCA	GGC	CCG	GGG
CAG	GAT	ACG	GAC	TGC	AGG	GAG	TGT	GAG	AGC	GGC	TCC
TTC	ACC	GCT	TCA	GAA	AAC	CAC	CTC	AGA	CAC	TGC	CTC
AGC	TGC	TCC	AAA	TGC	CGA	AAG	GAA	ATG	GGT	CAG	GTG
GAG	ATC	TCT	TCT	TGC	ACA	GTG	GAC	CGG	GAC	ACC	GTG
TGT	GGC	TGC	AGG	AAG	AAC	CAG	TAC	CGG	CAT	TAT	TGG
AGT	GAA	AAC	CTT	TTC	CAG	TGC	TTC	AAT	TGC	AGC	CTC
TGC	CTC	AAT	GGG	ACC	GTG	CAC	CTC	TCC	TGC	CAG	GAG
AAA	CAG	AAC	ACC	GTG	TGC	ACC	TGC	CAT	GCA	GGT	TTC
TTT	CTA	AGA	GAA	AAC	GAG	TGT	GTC	TCC	TGT	AGT	AAC
TGT	AAG	AAA	AGC	CTG	GAG	TGC	ACG	AAG	TTG	TGC	CTA
CCC	CAG	ATT	GAG	AAT	GTT	AAG	GGC	ACT	GAG	GAC	TCA
GGC	ACC	ACA									

, or a C- and/or N- terminally shortened sequence thereof;

C) DNA comprising the sequence:

ATG	GAT	AGT	GTG	TGT	CCC	CAA	GGA	AAA	TAT	ATC	CAC
CCT	CAA	AAT	AAT	TCG	ATT	TGC	TGT	ACC	AAG	TGC	CAC
AAA	GGA	ACC	TAC	TTG	TAC	AAT	GAC	TGT	CCA	GGC	CCG
GGG	CAG	GAT	ACG	GAC	TGC	AGG	GAG	TGT	GAG	AGC	GGC
TCC	TTC	ACC	GCT	TCA	GAA	AAC	CAC	CTC	AGA	CAC	TGC
CTC	AGC	TGC	TCC	AAA	TGC	CGA	AAG	GAA	ATG	GGT	CAG
GTG	GAG	ATC	TCT	TCT	TGC	ACA	GTG	GAC	CGG	GAC	ACC
GTG	TGT	GGC	TGC	AGG	AAG	AAC	CAG	TAC	CGG	CAT	TAT
TGG	AGT	GAA	AAC	CTT	TTC	CAG	TGC	TTC	AAT	TGC	AGC
CTC	TGC	CTC	AAT	GGG	ACC	GTG	CAC	CTC	TCC	TGC	CAG
GAG	AAA	CAG	AAC	ACC	GTG	TGC	ACC	TGC	CAT	GCA	GGT
TTC	TTT	CTA	AGA	GAA	AAC	GAG	TGT	GTC	TCC	TGT	AGT
AAC	TGT	AAG	AAA	AGC	CTG	GAG	TGC	ACG	AAG	TTG	TGC
CTA	CCC	CAG	ATT	GAG	AAT						

, or a C- and/or N- terminally shortened sequence thereof;

D) DNA comprising the sequence:

ATG	GAT	AGT	GTG	TGT	CCC	CAA	GGA	AAA	TAT	ATC	CAC
CCT	CAA	AAT	AAT	TCG	ATT	TGC	TGT	ACC	AAG	TGC	CAC
AAA	GGA	ACC	TAC	TTG	TAC	AAT	GAC	TGT	CCA	GGC	CCG
GGG	CAG	GAT	ACG	GAC	TGC	AGG	GAG	TGT	GAG	AGC	GGC
TCC	TTC	ACC	GCT	TCA	GAA	AAC	CAC	CTC	AGA	CAC	TGC

CTC	AGC	TGC	TCC	AAA	TGC	CGA	AAG	GAA	ATG	GGT	CAG
GTG	GAG	ATC	TCT	TCT	TGC	ACA	GTG	GAC	CGG	GAC	ACC
GTG	TGT	GGC	TGC	AGG	AAG	AAC	CAG	TAC	CGG	CAT	TAT
TGG	AGT	GAA	AAC	CTT	TTC	CAG	TGC	TTC	AAT	TGC	AGC
CTC	TGC	CTC	AAT	GGG	ACC	GTG	CAC	CTC	TCC	TGC	CAG
GAG	AAA	CAG	AAC	ACC	GTG	TGC	ACC	TGC	CAT	GCA	GGT
TTC	TTT	CTA	AGA	GAA	AAC	GAG	TGT	GTC	TCC	TGT	AGT
AAC	TGT	AAG	AAA	AGC	CTG	GAG	TGC	ACG	AAG	TTG	TGC
CTA	CCC	CAG	ATT	GAG	AAT	GTT	AAG	GGC	ACT	GAG	GAC
TCA	GGC	ACC	ACA								

, or a C- and/or N- terminally shortened sequence thereof;

E) DNA comprising the sequence:

ATG	GGC	CTC	TCC	ACC	GTG	CCT	GAC	CTG	CTG	CTG	CCA
CTG	GTG	CTC	CTG	GAG	CTG	TTG	GTG	GGA	ATA	TAC	CCC
TCA	GGG	GTT	ATT	GGA	CTG	GTC	CCT	CAC	CTA	GGG	GAC
AGG	GAG	AAG	AGA	GAT	AGT	GTG	TGT	CCC	CAA	GGA	AAA
TAT	ATC	CAC	CCT	CAA	AAT	AAT	TCG	ATT	TGC	TGT	ACC
AAG	TGC	CAC	AAA	GGA	ACC	TAC	TTG	TAC	AAT	GAC	TGT
CCA	GGC	CCG	GGG	CAG	GAT	ACG	GAC	TGC	AGG	GAG	TGT
GAG	AGC	GGC	TCC	TTC	ACC	GCT	TCA	GAA	AAC	CAC	CTC
AGA	CAC	TGC	CTC	AGC	TGC	TCC	AAA	TGC	CGA	AAG	GAA
ATG	GGT	CAG	GTG	GAG	ATC	TCT	TCT	TGC	ACA	GTG	GAC
CGG	GAC	ACC	GTG	TGT	GGC	TGC	AGG	AAG	AAC	CAG	TAC
CGG	CAT	TAT	TGG	AGT	GAA	AAC	CTT	TTC	CAG	TGC	TTC
AAT	TGC	AGC	CTC	TGC	CTC	AAT	GGG	ACC	GTG	CAC	CTC
TCC	TGC	CAG	GAG	AAA	CAG	AAC	ACC	GTG	TGC	ACC	TGC
CAT	GCA	GGT	TTC	TTT	CTA	AGA	GAA	AAC	GAG	TGT	GTC
TCC	TGT	AGT	AAC	TGT	AAG	AAA	AGC	CTG	GAG	TGC	ACG
AAG	TTG	TGC	CTA	CCC	CAG	ATT	GAG	AAT			

, or a C- and/or N- terminally shortened sequence thereof;

F) DNA comprising the sequence:

ATG	GGC	CTC	TCC	ACC	GTG	CCT	GAC	CTG	CTG	CTG	CCA
CTG	GTG	CTC	CTG	GAG	CTG	TTG	GTG	GGA	ATA	TAC	CCC
TCA	GGG	GTT	ATT	GGA	CTG	GTC	CCT	CAC	CTA	GGG	GAC
AGG	GAG	AAG	AGA	GAT	AGT	GTG	TGT	CCC	CAA	GGA	AAA
TAT	ATC	CAC	CCT	CAA	AAT	AAT	TCG	ATT	TGC	TGT	ACC
AAG	TGC	CAC	AAA	GGA	ACC	TAC	TTG	TAC	AAT	GAC	TGT
CCA	GGC	CCG	GGG	CAG	GAT	ACG	GAC	TGC	AGG	GAG	TGT
GAG	AGC	GGC	TCC	TTC	ACC	GCT	TCA	GAA	AAC	CAC	CTC
AGA	CAC	TGC	CTC	AGC	TGC	TCC	AAA	TGC	CGA	AAG	GAA
ATG	GGT	CAG	GTG	GAG	ATC	TCT	TCT	TGC	ACA	GTG	GAC

CGG	GAC	ACC	GTG	TGT	GGC	TGC	AGG	AAG	AAC	CAG	TAC
CGG	CAT	TAT	TGG	AGT	GAA	AAC	CTT	TTC	CAG	TGC	TTC
AAT	TGC	AGC	CTC	TGC	CTC	AAT	GGG	ACC	GTG	CAC	CTC
TCC	TGC	CAG	GAG	AAA	CAG	AAC	ACC	GTG	TGC	ACC	TGC
CAT	GCA	GGT	TTC	TTT	CTA	AGA	GAA	AAC	GAG	TGT	GTC
TCC	TGT	AGT	AAC	TGT	AAG	AAA	AGC	CTG	GAG	TGC	ACG
AAG	TTG	TGC	CTA	CCC	CAG	ATT	GAG	AAT	GTT	AAG	GGC
ACT	GAG	GAC	TCA	GGC	ACC	ACA					

, or a C- and/or N- terminally shortened sequence thereof;

G) DNA comprising the sequence:

ATG	GGC	CTC	TCC	ACC	GTG	CCT	GAC	CTG	CTG	CTG	CCA
CTG	GTG	CTC	CTG	GAG	CTG	TTG	GTG	GGA	ATA	TAC	CCC
TCA	GGG	GTT	ATT	GGA	GAT	AGT	GTG	TGT	CCC	CAA	GGA
AAA	TAT	ATC	CAC	CCT	CAA	AAT	AAT	TCG	ATT	TGC	TGT
ACC	AAG	TGC	CAC	AAA	GGA	ACC	TAC	TTG	TAC	AAT	GAC
TGT	CCA	GGC	CCG	GGG	CAG	GAT	ACG	GAC	TGC	AGG	GAG
TGT	GAG	AGC	GGC	TCC	TTC	ACC	GCT	TCA	GAA	AAC	CAC
CTC	AGA	CAC	TGC	CTC	AGC	TGC	TCC	AAA	TGC	CGA	AAG
GAA	ATG	GGT	CAG	GTG	GAG	ATC	TCT	TCT	TGC	ACA	GTG
GAC	CGG	GAC	ACC	GTG	TGT	GGC	TGC	AGG	AAG	AAC	CAG
TAC	CGG	CAT	TAT	TGG	AGT	GAA	AAC	CTT	TTC	CAG	TGC
TTC	AAT	TGC	AGC	CTC	TGC	CTC	AAT	GGG	ACC	GTG	CAC
CTC	TCC	TGC	CAG	GAG	AAA	CAG	AAC	ACC	GTG	TGC	ACC
TGC	CAT	GCA	GGT	TTC	TTT	CTA	AGA	GAA	AAC	GAG	TGT
GTC	TCC	TGT	AGT	AAC	TGT	AAG	AAA	AGC	CTG	GAG	TGC
ACG	AAG	TTG	TGC	CTA	CCC	CAG	ATT	GAG	AAT		

, or a C- and/or N- terminally shortened sequence thereof;

H) DNA comprising the sequence:

ATG	GGC	CTC	TCC	ACC	GTG	CCT	GAC	CTG	CTG	CTG	CCA
CTG	GTG	CTC	CTG	GAG	CTG	TTG	GTG	GGA	ATA	TAC	CCC
TCA	GGG	GTT	ATT	GGA	GAT	AGT	GTG	TGT	CCC	CAA	GGA
AAA	TAT	ATC	CAC	CCT	CAA	AAT	AAT	TCG	ATT	TGC	TGT
ACC	AAG	TGC	CAC	AAA	GGA	ACC	TAC	TTG	TAC	AAT	GAC
TGT	CCA	GGC	CCG	GGG	CAG	GAT	ACG	GAC	TGC	AGG	GAG
TGT	GAG	AGC	GGC	TCC	TTC	ACC	GCT	TCA	GAA	AAC	CAC
CTC	AGA	CAC	TGC	CTC	AGC	TGC	TCC	AAA	TGC	CGA	AAG
GAA	ATG	GGT	CAG	GTG	GAG	ATC	TCT	TCT	TGC	ACA	GTG
GAC	CGG	GAC	ACC	GTG	TGT	GGC	TGC	AGG	AAG	AAC	CAG
TAC	CGG	CAT	TAT	TGG	AGT	GAA	AAC	CTT	TTC	CAG	TGC
TTC	AAT	TGC	AGC	CTC	TGC	CTC	AAT	GGG	ACC	GTG	CAC

CTC	TCC	TGC	CAG	GAG	AAA	CAG	AAC	ACC	GTG	TGC	ACC
TGC	CAT	GCA	GGT	TTC	TTT	CTA	AGA	GAA	AAC	GAG	TGT
GTC	TCC	TGT	AGT	AAC	TGT	AAG	AAA	AGC	CTG	GAG	TGC
ACG	AAG	TTG	TGC	CTA	CCC	CAG	ATT	GAG	AAT	GTT	AAG
GGC	ACT	GAG	GAC	TCA	GGC	ACC	ACA				

, or a C- and/or N- terminally shortened sequence thereof; and

I) DNA comprising the sequence:

ATG	GGC	CTC	TCC	ACC	GTG	CCT	GAC	CTG	CTG	CTG	CCA
CTG	GTG	CTC	CTG	GAG	CTG	TTG	GTG	GGA	ATA	TAC	CCC
TCA	GGG	GTT	ATT	GGA	CTG	GTC	CCT	CAC	CTA	GGG	GAC
AGG	GAG	AAG	AGA	GAT	AGT	GTG	TGT	CCC	CAA	GGA	AAA
TAT	ATC	CAC	CCT	CAA	AAT	AAT	TCG	ATT	TGC	TGT	ACC
AAG	TGC	CAC	AAA	GGA	ACC	TAC	TTG	TAC	AAT	GAC	TGT
CCA	GGC	CCG	GGG	CAG	GAT	ACG	GAC	TGC	AGG	GAG	TGT
GAG	AGC	GGC	TCC	TTC	ACC	GCT	TCA	GAA	AAC	CAC	CTC
AGA	CAC	TGC	CTC	AGC	TGC	TCC	AAA	TGC	CGA	AAG	GAA
ATG	GGT	CAG	GTG	GAG	ATC	TCT	TCT	TGC	ACA	GTG	GAC
CGG	GAC	ACC	GTG	TGT	GGC	TGC	AGG	AAG	AAC	CAG	TAC
CGG	CAT	TAT	TGG	AGT	GAA	AAC	CTT	TTC	CAG	TGC	TTC
AAT	TGC	AGC	CTC	TGC	CTC	AAT	GGG	ACC	GTG	CAC	CTC
TCC	TGC	CAG	GAG	AAA	CAG	AAC	ACC	GTG	TGC	ACC	TGC
CAT	GCA	GGT	TTC	TTT	CTA	AGA	GAA	AAC	GAG	TGT	GTC
TCC	TGT	AGT	AAC	TGT	AAG	AAA	AGC	CTG	GAG	TGC	ACG
AAG	TTG	TGC	CTA	CCC	CAG	ATT	GAG	AAT	GTT	AAG	GGC
ACT	GAG	GAC	TCA	GGC	ACC	ACA	GTG	CTG	TTG	CCC	CTG
GTC	ATT	TTC	TTT	GGT	CTT	TGC	CTT	TTA	TCC	CTC	CTC
TTC	ATT	GGT	TTA	ATG	TAT	CGC	TAC	CAA	CGG	TGG	AAG
TCC	AAG	CTC	TAC	TCC	ATT	GTT	TGT	GGG	AAA	TCG	ACA
CCT	GAA	AAA	GAG	GGG	GAG	CTT	GAA	GGA	ACT	ACT	ACT
AAG	CCC	CTG	GCC	CCA	AAC	CCA	AGC	TTC	AGT	CCC	ACT
CCA	GGC	TTC	ACC	CCC	ACC	CTG	GGC	TTC	AGT	CCC	GTG
CCC	AGT	TCC	ACC	TTC	ACC	TCC	AGC	TCC	ACC	TAT	ACC
CCC	GGT	GAC	TGT	CCC	AAC	TTT	GCG	GCT	CCC	CGC	AGA
GAG	GTG	GCA	CCA	CCC	TAT	CAG	GGG	GCT	GAC	CCC	ATC
CTT	GCG	ACA	GCC	CTC	GCC	TCC	GAC	CCC	ATC	CCC	AAC
CCC	CTT	CAG	AAG	TGG	GAG	GAC	AGC	GCC	CAC	AAG	CCA
CAG	AGC	CTA	GAC	ACT	GAT	GAC	CCC	GCG	ACG	CTG	TAC
GCC	GTG	GTG	GAG	AAC	GTG	CCC	CCG	TTG	CGC	TGG	AAG
GAA	TTC	GTG	CGG	CGC	CTA	GGG	CTG	AGC	GAC	CAC	GAG
ATC	GAT	CGG	CTG	GAG	CTG	CAG	AAC	GGG	CGC	TGC	CTG
CGC	GAG	GCG	CAA	TAC	AGC	ATG	CTG	GCG	ACC	TGG	AGG
CGG	CGC	ACG	CCG	CGG	CGC	GAG	GCC	ACG	CTG	GAG	CTG

CTG GGA CGC GTG CTC CGC GAC ATG GAC CTG CTG GGC
TGC CTG GAG GAC ATC GAG GAG GCG CTT TGC GGC CCC
GCC GCC CTC CCG CCC GCG CCC AGT CTT CTC AGA

, or a C- and/or N- terminally shortened sequence thereof;

J) a DNA sequence of A, B, C, D, E, F, G, H or I encoding at least one conservative amino acid substitution;

K) a DNA sequence of A, B, C, D, E, F, G, H or I encoding at least one amino acid substitution at a glycosylation site;

L) a DNA sequence of A, B, C, D, E, F, G, H or I encoding at least one amino acid substitution at a proteolytic cleavage site; and

M) a DNA sequence of A, B, C, D, E, F, G, H or I encoding at least one amino acid substitution at a cysteine residue.

82. (Amended) A recombinant polypeptide which is nonglycosylated or is glycosylated by a CHO cell which and has the ability to bind to TNF, characterized in that the polypeptide is encoded by a nucleic acid which hybridizes with DNA complementary to the DNA defined in claim 69 under conditions of moderate stringency.

83. (Amended) A recombinant polypeptide which is nonglycosylated or is glycosylated by a CHO cell and has the ability to bind to TNF, wherein said polypeptide is selected from the group consisting of:

A) a polypeptide comprising the amino acid sequence:

R ²	asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn
	asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu
	tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg
	glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu
	arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly
	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val
	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu
	asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly
	thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys
	thr	cys	his	ala	gly	phe	phe	ieu	arg	glu	asn	glu	cys	val
	ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu
	cys	leu	pro	gln	ile	glu	asn							

, or a C- and/or N- terminally shortened sequence thereof, wherein R² is absent or is a polypeptide which can be cleaved *in vivo*;

B) a polypeptide comprising the amino acid sequence:

R ²	asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn
	asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu
	tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg
	glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu
	arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly
	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val
	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu
	asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly
	thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys
	thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val
	ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu
	cys	leu	pro	gln	ile	glu	asn	val	lys	gly	thr	glu	asp	ser
	gly	thr	thr											

, or a C- and/or N- terminally shortened sequence thereof, wherein R² is absent or is a polypeptide which can be cleaved *in vivo*;

C) a polypeptide comprising the amino acid sequence of A or B with at least one conservative amino acid substitution;

D) a polypeptide comprising the amino acid sequence of A or B with at least one amino acid substitution at a glycosylation site;

E) a polypeptide comprising the amino acid sequence of A or B with at least one amino acid substitution at a proteolytic cleavage site; and

F) a polypeptide comprising the amino acid sequence of A or B with at least one amino acid substitution at a cysteine residue.

84. (Amended) A polypeptide according to claim 83, wherein R² is a polypeptide comprising an amino acid sequence which can be cleaved *in vivo*.

85. (Amended) A polypeptide according to claim 84, wherein R² is a polypeptide comprising the amino acid sequence:

met	gly	leu	ser	thr	val	pro	asp	leu	leu	leu	pro	leu	val
leu	leu	glu	leu	leu	val	gly	ile	tyr	pro	ser	gly	val	ile

gly;

or a C- and/or N- terminally shortened sequence thereof.

95. (Amended) A recombinant polypeptide which is nonglycosylated or is glycosylated by a CHO cell and has the ability to bind to TNF, characterized in that the polypeptide is encoded by a nucleic acid which hybridizes with DNA complementary to the DNA defined in claim 83 under conditions of moderate stringency.

96. (Amended) A polypeptide according to claim 83, wherein said polypeptide is selected from the group consisting of:

A) a polypeptide comprising the amino acid sequence:

asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn
asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu
tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg
glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu
arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly
gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val
cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu
asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly
thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys
thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val
ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu
cys	leu	pro	gln	ile	glu	asn							

, or a C- and/or N- terminally shortened sequence thereof;

B) a polypeptide comprising the amino acid sequence:

leu	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser	val
cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	ser	ile
cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn	asp

cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg	glu	cys	glu
ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu	arg	his	cys
leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly	gln	val	glu
ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val	cys	gly	cys
arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu	asn	leu	phe
gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly	thr	val	his
leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys	thr	cys	his
ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys	ser
asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu	pro
gln	ile	glu	asn										

, or a C- and/or N- terminally shortened sequence thereof;

C) a polypeptide comprising the amino acid sequence:

asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn
asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu
tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg
glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu
arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly
gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val
cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu
asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly
thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys
thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val
ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu
cys	leu	pro	gln	ile	glu	asn	val	lys	gly	thr	glu	asp	ser
gly	thr	thr											

, or a C- and/or N- terminally shortened sequence thereof; and

D) a polypeptide comprising the amino acid sequence:

leu	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser	val
cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	ser	ile
cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn	asp
cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg	glu	cys	glu
ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu	arg	his	cys
leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly	gln	val	glu
ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val	cys	gly	cys
arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu	asn	leu	phe
gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly	thr	val	his
leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys	thr	cys	his
ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys	ser
asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu	pro
gln	ile	glu	asn	val	lys	gly	thr	glu	asp	ser	gly	thr	thr

, or a C- and/or N- terminally shortened sequence thereof;

E) a polypeptide comprising the amino acid sequence of A, B, C or D with at least one conservative amino acid substitution;

F) a polypeptide comprising the amino acid sequence of A, B, C or D with at least one amino acid substitution at a glycosylation site;

G) a polypeptide comprising the amino acid sequence of A, B, C or D with at least one amino acid substitution at a proteolytic cleavage site; and

H) a polypeptide comprising the amino acid sequence of A, B, C or D with at least one amino acid substitution at a cysteine residue.

97. (Amended) A polypeptide according to claim 96, wherein said polypeptide includes at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and at the carboxyl-terminus.

98. (Amended) A polypeptide according to claim 97, wherein said polypeptide includes at least one additional amino acid at the amino-terminus and at the carboxyl-terminus.

99. (Amended) A polypeptide according to claim 97, wherein said polypeptide includes at least one additional amino acid at the amino-terminus.

100. (Amended) A polypeptide according to claim 99, wherein said polypeptide includes a methionine at the amino-terminus.

101. (Amended) A polypeptide according to claim 97, wherein said polypeptide includes at least one additional amino acid at the carboxyl-terminus.

102. (Amended) A polypeptide according to claim 96, wherein said polypeptide is not associated with human urinary proteins.

103. (Amended) A recombinant polypeptide which is nonglycosylated or is glycosylated by a CHO cell and has the ability to bind to TNF, wherein said polypeptide is selected from the group consisting of :

A) a polypeptide comprising the amino acid sequence:

met	asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln
asn	asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr
leu	tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys
arg	glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his
leu	arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met
gly	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr
val	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser
glu	asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn
gly	thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val
cys	thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys
val	ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys
leu	cys	leu	pro	gln	ile	glu	asn,						

or a C- and/or N- terminally shortened sequence thereof;

B) a polypeptide comprising the amino acid sequence:

met	leu	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser
val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	ser
ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn
asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg	glu	cys
glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu	arg	his
cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly	gln	val
glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val	cys	gly
cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu	asn	leu
phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly	thr	val
his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys	thr	cys
his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys
ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu
pro	gln	ile	glu	asn									

, or a C- and/or N- terminally shortened sequence thereof;

C) a polypeptide comprising the amino acid sequence:

met	asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln
asn	asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr
leu	tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys
arg	glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his
leu	arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met
gly	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr
val	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser
glu	asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn
gly	thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val
cys	thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys
val	ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys
leu	cys	leu	pro	gln	ile	glu	asn	val	lys	gly	thr	glu	asp
ser	gly	thr	thr										

, or a C- and/or N- terminally shortened sequence thereof;

D) a polypeptide comprising the amino acid sequence:

met	leu	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser
val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	ser
ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn
asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg	glu	cys
glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu	arg	his
cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly	gln	val
glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val	cys	gly
cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu	asn	leu
phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly	thr	val
his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys	thr	cys
his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys
ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu
pro	gln	ile	glu	asn	val	lys	gly	thr	glu	asp	ser	gly	thr
thr													

, or a C- and/or N- terminally shortened sequence thereof;

E) a polypeptide comprising the amino acid sequence:

met	gly	leu	ser	thr	val	pro	asp	leu	leu	leu	pro	leu	val
leu	leu	glu	leu	leu	val	gly	ile	tyr	pro	ser	gly	val	ile
gly	leu	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser
val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	ser
ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn
asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg	glu	cys
glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu	arg	his
cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly	gln	val
glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val	cys	gly

cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu	asn	leu
phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly	thr	val
his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys	thr	cys
his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys
ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu
pro	gln	ile	glu	asn									

, or a C- and/or N- terminally shortened sequence thereof;

F) a polypeptide comprising the amino acid sequence:

met	gly	leu	ser	thr	val	pro	asp	leu	leu	leu	pro	leu	val
leu	leu	glu	leu	leu	val	gly	ile	tyr	pro	ser	gly	val	ile
gly	leu	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser
val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	ser
ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn
asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg	glu	cys
glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu	arg	his
cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly	gln	val
glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val	cys	gly
cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu	asn	leu
phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly	thr	val
his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys	thr	cys
his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys
ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu
pro	gln	ile	glu	asn	val	lys	gly	thr	glu	asp	ser	gly	thr

, or a C- and/or N- terminally shortened sequence thereof;

G) a polypeptide comprising the amino acid sequence:

met	gly	leu	ser	thr	val	pro	asp	leu	leu	leu	pro	leu	val
leu	leu	glu	leu	leu	val	gly	ile	tyr	pro	ser	gly	val	ile
gly	asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln
asn	asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr
leu	tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys
arg	glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his
leu	arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met
gly	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr
val	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser
glu	asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn
gly	thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val
cys	thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys
val	ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys
leu	cys	leu	pro	gln	ile	glu	asn						

, or a C- and/or N- terminally shortened sequence thereof;

H) a polypeptide comprising the amino acid sequence:

met	gly	leu	ser	thr	val	pro	asp	leu	leu	leu	pro	leu	val
leu	leu	glu	leu	leu	val	gly	ile	tyr	pro	ser	gly	val	ile
gly	asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln
asn	asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr
leu	tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys
arg	glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his
leu	arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met
gly	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr
val	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser
glu	asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn
gly	thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val
cys	thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys
val	ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys
leu	cys	leu	pro	gln	ile	glu	asn	val	lys	gly	thr	glu	asp
ser	gly	thr	thr										

, or a C- and/or N- terminally shortened sequence thereof;

I) a polypeptide comprising the amino acid sequence:

met	gly	leu	ser	thr	val	pro	asp	leu	leu	leu	pro	leu	val
leu	leu	glu	leu	leu	val	gly	ile	tyr	pro	ser	gly	val	ile
gly	leu	val	pro	his	leu	gly	asp	arg	glu	lys	arg	asp	ser
val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn	asn	ser
ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu	tyr	asn
asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg	glu	cys
glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu	arg	his
cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly	gln	val
glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val	cys	gly
cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu	asn	leu
phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly	thr	val
his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys	thr	cys
his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val	ser	cys
ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu	cys	leu
pro	gln	ile	glu	asn	val	lys	gly	thr	glu	asp	ser	gly	thr
thr	val	leu	leu	pro	leu	val	ile	phe	phe	gly	leu	cys	leu
leu	ser	leu	leu	phe	ile	gly	leu	met	tyr	arg	tyr	gln	arg
trp	lys	ser	lys	leu	tyr	ser	ile	val	cys	gly	lys	ser	thr
pro	glu	lys	glu	gly	glu	leu	glu	gly	thr	thr	thr	lys	pro
leu	ala	pro	asn	pro	ser	phe	ser	pro	thr	pro	gly	phe	thr
pro	thr	leu	gly	phe	ser	pro	val	pro	ser	ser	thr	phe	thr

ser	ser	ser	thr	tyr	thr	pro	gly	asp	cys	pro	asn	phe	ala
ala	pro	arg	arg	glu	val	ala	pro	pro	tyr	gln	gly	ala	asp
pro	ile	leu	ala	thr	ala	leu	ala	ser	asp	pro	ile	pro	asn
pro	leu	gln	lys	trp	glu	asp	ser	ala	his	lys	pro	gln	ser
leu	asp	thr	asp	asp	pro	ala	thr	leu	tyr	ala	val	val	glu
asn	val	pro	pro	leu	arg	trp	lys	glu	phe	val	arg	arg	leu
gly	leu	ser	asp	his	glu	ile	asp	arg	leu	glu	leu	gln	asn
gly	arg	cys	leu	arg	glu	ala	gln	tyr	ser	met	leu	ala	thr
trp	arg	arg	arg	thr	pro	arg	arg	glu	ala	thr	leu	glu	leu
leu	gly	arg	val	leu	arg	asp	met	asp	leu	leu	gly	cys	leu
glu	asp	ile	glu	glu	ala	leu	cys	gly	pro	ala	ala	leu	pro
pro	ala	pro	ser	leu	leu	arg							

, or a C- and/or N- terminally shortened sequence thereof;

J) a polypeptide comprising the amino acid sequence of A, B, C, D, E, F, G, H, or I with at least one conservative amino acid substitution;

K) a polypeptide comprising the amino acid sequence of A, B, C, D, E, F, G, H, or I with at least one amino acid substitution at a glycosylation site;

L) a polypeptide comprising the amino acid sequence of A, B, C, D, E, F, G, H, or I with at least one amino acid substitution at a proteolytic cleavage site; and

M) a polypeptide comprising the amino acid sequence of A, B, C, D, E, F, G, H, or I with at least one amino acid substitution at a cysteine residue.

104. (Amended) A polypeptide according to claim 103, wherein said polypeptide includes at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and at the carboxyl-terminus.

105. (Amended) A polypeptide according to claim 104, wherein said polypeptide includes at least one additional amino acid at the carboxyl-terminus.

107. A polypeptide according to claim 103, wherein said polypeptide is chemically derivatized.

108. A polypeptide having the ability to bind to TNF comprising an amino acid sequence as set forth in one of claims 69, 78, 80, 83, 96 and 103 with at least one intrasequence conservative amino acid substitution.

109. (Amended) A polypeptide according to claim 108, wherein said polypeptide includes at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and at the carboxyl-terminus.

110. (Amended) A polypeptide according to claim 109, wherein said polypeptide includes at least one additional amino acid at the amino-terminus and at the carboxyl-terminus.

111. (Amended) A polypeptide according to claim 108, wherein said polypeptide includes at least one additional amino acid at the amino-terminus.

112. (Amended) A polypeptide according to claim 111, wherein said polypeptide includes a methionine at the amino-terminus.

113. (Amended) A polypeptide according to claim 109, wherein said polypeptide includes at least one additional amino acid at the carboxyl-terminus.

114. (Amended) A polypeptide according to claim 108, wherein said polypeptide includes a methionine at the amino-terminus and said amino acid substitution is at a glycosylation site.

115. (Amended) A polypeptide according to claim 108, wherein said amino acid substitution is at a glycosylation site.

Raw Sequence Listing Error Summary

ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER:

08/484312

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2 Wrapped Aminos The amino acid number/text at the end of each line "wrapped " down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3 J Incorrect Line Length The rules require that a line not exceed 72 characters in length. This includes spaces.
All text must be visible on page.
- 4 Misaligned Amino Acid The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs
Numbering between the numbering. It is recommended to delete any tabs and uses spacing between the numbers.
- 5 Non-ASCII This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 6 Variable Length Sequence(s) contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and
indicate in the (ix) features section that some may be missing.
- 7 Wrong Designation Sequence(s) contain amino acid or nucleic acid designators which are not standard
representations as per the Sequence Rules (Please refer to paragraph 1.822)
- 8 Skipped Sequences Sequence(s) missing. If intentional, please use the following format for each skipped sequence:
(OLD RULES) (2) INFORMATION FOR SEQ ID NO:X:
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:
This sequence is intentionally skipped

Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 9 Skipped Sequences Sequence(s) missing. If intentional, please use the following format for each skipped sequence.
(NEW RULES) <210> sequence id number
 <400> sequence id number
 000
- 10 Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing.
(NEW RULES) Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 11 Use of <213>Organism Sequence(s) are missing this mandatory field or its response.
(NEW RULES)
- 12 Use of <220>Feature Sequence(s) are missing the <220>Feature and associated headings.
(NEW RULES) Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"
Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32)
(Sec. 1.823 of new Sequence Rules)
- 13 PatentIn ver. 2.0 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted
file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
Instead, please use "File Manager" or any other means to copy file to floppy disk.